Position in NVS
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$171,451
+$4,343 QoQ
Shares Held
1,094
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#1,331
of 1,603 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FOSTER DYKEMA CABOT & PARTNERS, LLC holds $37,893,315 across 11 Drug Manufacturers - General names. NVS ranks #6 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
28,025 | $33,614,028 | |
| 2 | JNJ |
Johnson & Johnson
|
5,153 | $1,308,707 | |
| 3 | MRK |
Merck & Co., Inc.
|
8,626 | $1,108,441 | |
| 4 | ABBV |
AbbVie Inc.
|
3,815 | $960,006 | |
| 5 | NVO |
Novo Nordisk A S
|
4,526 | $216,976 | |
| 6 | NVS |
Novartis AG
This page
|
1,094 | $171,451 | |
| 7 | AZN |
Astrazeneca PLC
|
820 | $155,488 | |
| 8 | AMGN |
Amgen Inc
|
420 | $152,090 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $171,451 | 1,094 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $167,108 | 1,094 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $150,829 | 1,094 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $140,294 | 1,094 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $132,384 | 1,094 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $121,959 | 1,094 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $113,171 | 1,163 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $145,615 | 1,266 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $99,646 | 936 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $90,539 | 936 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||